Donald Robertson, DO
Internal Medicine · Iuka, MSNPI 1538297593
Payments from drug & device makers
Across 407 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$731
- AstraZeneca$612
- AbbVie$579
- Pfizer$500
- Amgen$456
- GSK$428
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,090100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $731 |
| AstraZeneca | 28 | $612 |
| AbbVie(2 entities) | 51 | $579 |
| Pfizer | 33 | $500 |
| Amgen | 32 | $456 |
| GSK | 34 | $428 |
| Boehringer Ingelheim | 25 | $396 |
| Lilly USA, LLC | 29 | $392 |
| Otsuka America Pharmaceutical, Inc. | 14 | $307 |
| Johnson & Johnson | 14 | $212 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $195 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $114 |
| Merck | 9 | $112 |
| Abbott | 4 | $92 |
| Axsome Therapeutics, Inc. | 3 | $90 |
| Daiichi Sankyo Inc. | 5 | $87 |
| Ironwood Pharmaceuticals, Inc | 5 | $86 |
| Vifor Pharma, Inc. | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $66 |
| Amarin Pharma, Inc. | 3 | $65 |
| Lundbeck LLC | 2 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $48 |
| Genentech USA, Inc. | 3 | $42 |
| Mylan Specialty L.p. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,090 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 104 | $144,677 |
| EliquisApixaban | 148 | $76,138 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $55,108 |
| JardianceEmpagliflozin | 53 | $51,677 |
| FarxigaDapagliflozin Propanediol | 58 | $43,294 |
| JanuviaSitagliptin Phosphate | 82 | $39,436 |
| JanumetSitagliptin Phos/Metformin Hcl | 36 | $27,218 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $24,582 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $20,024 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $18,570 |
| InvokanaCanagliflozin | 33 | $18,510 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $17,958 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $16,512 |
| MyrbetriqMirabegron | 41 | $16,390 |
| LinzessLinaclotide | 14 | $15,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $731 | $144,677104 claims |
| MerckJanuvia, Janumet, Janumet Xr | $112 | $83,166137 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $396 | $80,50588 claims |
| PfizerEliquis | $500 | $76,138148 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $428 | $69,14472 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $612 | $61,86376 claims |
| Johnson & JohnsonInvokana, Xarelto | $212 | $30,32352 claims |
| AbbVieLinzess, Synthroid | $579 | $18,40465 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $16,39041 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $114 | $11,12821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Iuka
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.